KDR and ovarian carcinoma: In ovarian cancer, bevacizumab significantly increases progression‐free survival (PFS) compared with chemotherapy alone in advanced disease, and more recently VEGFR‐targeting agents were shown to significantly increase PFS (Eskander & Tewari, 2014) and overall survival (OS; Witteveen et al, 2013).